Comparison of the effect of urokinase and batroxobin in the treatment of acute cerebral infarction
10.3760/cma.j.issn.1008-6706.2017.08.011
- VernacularTitle:尿激酶与阿替普酶治疗急性脑梗死效果比较
- Author:
Xiaodong ZHAO
- Keywords:
Cerebral infarction;
Urokinase;
Alteplase
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(8):1165-1168
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of urokinase and batroxobin in the treatment of acute cerebral infarction(ACI).Methods According to the digital table,88 patients with ACI were randomly divided into two groups.The observation group (44 cases) was given thrombolytic therapy,the control group (44 cases) was given alteplase treatment.The treatment effects and safety were compared between the two groups.Results The NIHSS scores before treatment,24h,1 week and 2 weeks after thrombolysis had no statistically significant differences between the two groups (all P ＞ 0.05).After treatment for 1 month,29 cases (65.9 ％) of nerve function good progno sis in the observation group,28 cases(63.6％) in the control group,there was no significant difference between the two groups(x2 =0.049,P =0.958).In the control group,1 case of cerebral hemorrhage,and occlusion in 1 case,1 case of other adverse reactions (hematuria),the incidence rate of complications and adverse reaction was 6.82％ (3/44).In the observation group,2 cases of hemorrhage (including 1 case of cerebral hemorrhage and 1 case of gastrointestinal bleeding),1 case of reperfusion injury and restenosis,2 cases of other adverse reactions (including hematuria and allergic rash,each in 1 case),the incidence rate of complications and adverse reaction was 13.64％ (6/44).There was no statistically significant difference in the incidence rate of complications and adverse reaction between the two groups (x2 =0.495,P =0.597).Conclusion Urokinase and alteplase in the treatment of ACI have considerable effect in improving the symptoms of patients with neurologic impairment,alteplase is slightly in terms of security advantages,but the price is relatively expensive,urokinase in the treatment of ACI in primary hospital is still desirable.
